Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Drugs Inhibiting the KRAS Oncogene Suppress Growth of Pancreatic Tumors in Mouse Xenograft Model

By BiotechDaily International staff writers
Posted on 14 Jun 2013
Drugs that inhibit the activity of the enzyme GSK-3 alpha (glycogen synthase kinase 3 alpha) strongly suppress growth of human pancreatic tumor xenografts in mice as well as down regulate certain oncogenic NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) target genes.

GSK-3 has since been identified as a kinase for over forty different proteins in a variety of different pathways. In mammals, GSK-3 is encoded by two known genes, GSK-3 alpha and GSK-3 beta. GSK-3 has recently been the subject of intense research because it has been implicated in a number of diseases, including type II diabetes, Alzheimer's disease, inflammation, cancer, and bipolar disorder.

Investigators at the University of North Carolina (Chapel Hill, USA) have found that in pancreatic cancer cells GSK-3 alpha is upregulated by mutant KRAS (Kirsten rat sarcoma viral oncogene). The KRAS gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

In a paper published in the April 1, 2013, online edition of the journal Cancer Discovery, the investigators reported that GSK-3 alpha was required for promoting critical NF-kappaB signaling in pancreatic cancer cells. The transcription factors of the NF-kappaB family are upregulated in many human cancers. NF-kappaB has roles in all stages of carcinogenesis or cancer progression, including protection from cell death, increase of cell proliferation, cell motility and metastasis, tumor inflammation, and angiogenesis. In addition, tumor cells often acquire resistance to anticancer drugs by upregulating NF-kappaB signaling.

Pharmacologic inhibition of GSK-3 suppressed growth of human pancreatic tumor explants in mice, consistent with the loss of expression of oncogenic genes such as c-myc and TERT.

“GSK-3 promotes activity of a protein called NF-kappaB. Our lab has been studying NF-kappaB for a number of years and has published that this protein is important in KRAS signaling. But how KRAS activates NF-kappaB has not been well understood. We have found a link, ” said senior author Dr. Albert Baldwin, professor of biology at the University of North Carolina. “Our data suggest that GSK-3 alpha is really an onco-protein and that KRAS utilizes GSK-3 alpha to activate both NF-kappaB pathways, called canonical and noncanonical. This finding is important because GSK-3 alpha sits on top of the two pathways and inhibits them both, thus making it a viable therapeutic target. We are conducting further pharmacologic studies.”

Related Links:


University of North Carolina



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.